Professor Ian Judson’s Opinion

In response to regorafenib’s removal Professor Ian Judson, Head of the Sarcoma Unit at The Royal Marsden Hospital and Chair of the GIST Support UK Medical Advisory Board, stated: “The Cancer Drugs Fund was initially set up to give access to drugs deemed not to be cost effective by NICE, which has not appraised regorafenib for cost-effectiveness in this setting. The CDF press release says that they will not remove drugs from the list that are the only drug available for a given disease. However, regorafenib is the only treatment for GIST that is resistant to imatinib and sunitinib.”

Source: GIST Support UK Press Release 16-01-2015

No comments yet.

Leave a Reply

Built with our compliments, good luck from BN:Coded Ltd